pharma QA – Page 95 – Pharma.Tips

Dose Delivery Variability during lamination: inspection-ready documentation pack

Addressing Variability in Dose Delivery during Lamination: A Comprehensive Investigation In pharmaceutical manufacturing, particularly in the development of transdermal drug delivery systems, maintaining consistent dose delivery is crucial. When variability…

Texture Variability at accelerated stability: packaging compatibility and stability justification

Understanding Texture Variability During Accelerated Stability Testing in Pharmaceutical Manufacturing Texture variability observed during accelerated stability testing can raise significant concerns regarding product quality and consistency, particularly for topical and…

Ivpt Failure in transdermal patch manufacturing: packaging integrity and shelf-life justification

Investigation of IVPT Failures during Transdermal Patch Manufacturing: Packaging Integrity and Shelf-Life Considerations In the increasingly complex landscape of pharmaceutical manufacturing, ensuring the integrity and efficacy of transdermal patches poses…

Texture Variability during shared equipment campaign: GMP investigation and CAPA strategy

Investigating Texture Variability in Shared Equipment Campaigns: Identifying Causes and Implementing CAPA In the realm of pharmaceutical manufacturing, maintaining the quality of topical and dermatological dosage forms is paramount. One…

Drug Crystallization after backing material change: GMP investigation plan and CAPA

Understanding Drug Crystallization Following Changes to Backing Material: An Effective Investigation Framework In the pharmaceutical sector, changes in materials can yield unexpected issues, such as drug crystallization, particularly when dealing…

E&L Failure during method transfer: sampling, filtration, and EM controls

Addressing E&L Failures during Method Transfers: A Structured Investigation Approach During method transfers in pharmaceutical manufacturing, specifically in the production of ophthalmic dosage forms, extraction and leachable (E&L) failures can…

Ph Drift during homogenization: mixing and sampling controls for QA review

Understanding pH Drift During Homogenization and Ensuring Robust Mixing Controls for QA Review In pharmaceutical manufacturing, maintaining consistent product quality is critical for regulatory compliance and patient safety. One frequent…

Backing Delamination at accelerated stability: process parameter review and validation impact

Investigating Backing Delamination at Accelerated Stability: A Systematic Approach Backing delamination in transdermal drug delivery systems can significantly impact product integrity, therapeutic efficacy, and regulatory compliance. When delamination occurs during…

Tag: pharma QA

Dose Delivery Variability during lamination: inspection-ready documentation pack

Texture Variability at accelerated stability: packaging compatibility and stability justification

Ivpt Failure in transdermal patch manufacturing: packaging integrity and shelf-life justification

Texture Variability during shared equipment campaign: GMP investigation and CAPA strategy

Drug Crystallization after backing material change: GMP investigation plan and CAPA

E&L Failure during method transfer: sampling, filtration, and EM controls

Ph Drift during homogenization: mixing and sampling controls for QA review

Backing Delamination at accelerated stability: process parameter review and validation impact

Viscosity Drift during bulk hold: GMP investigation and CAPA strategy

Edge Lifting after adhesive change: root cause mapping across materials and process

Ccit Failure during method transfer: FDA-ready investigation report and batch disposition

E&L Failure after backing material change: GMP investigation plan and CAPA